Pathophysiology of Nervous System Disease

Research groups

Celullar and molecular basis of Huntington’s disease and other disorders of the basal ganglia

INTERCELLULAR COMMUNICATION

NEURAL DEVELOPMENT

GRUP DE RECERCA EN NEUROFARMACOLOGIA: PREVENCIÓ DE L’ENVELLIMENT (GREN)

NEUROPHARMACOLOGY AND PAIN

Physiology and pathology of the functional relations neuron-glia

NEURODEGENERATION AND SYNAPTIC DYSFUNCTION IN HUNTINGTON´S DISEASE

PHYSIOPATHOLOGY AND TOXICOLOGY OF SENSORY AND MOTOR SYSTEMS

NEUROPHARMACOLOGY IN AGING AND NEURODEGENERATION

BLOOD-BRAIN BARRIER RESEARCH GROUP

KINASES AND PHOSPHATASES IN NEURONAL FUNCTION AND DYSFUNCTION

Cellular and molecular neurobiology – Multiple sclerosis

Neurophyisiology Lab

MOLECULAR AND CELLULAR NEUROBIOTECHNOLOGY

NEUROINFLAMMATION GROUP

DEVELOPMENTAL NEUROBIOLOGY AND REGENERATION

NEURO-CELLTEC-UB

FUNCTIONAL GENOMICS OF NEURODEGENERATIVE DISEASES

HIPPOCAMPAL FUNCTION IN HEALTH AND DISEASE

NEURODEGENERATION AND NEUROPROTECTION

Representative of the research area

Prof. Mercè Pallas Lliberia

pallas (at) ub.edu

[rev_slider alias=”fisiopatologia”]

The study of the pathophysiology of nervous system diseases is an important challenge in Biomedicine to develop new successful therapies.

 

Neurological and psychiatric disorders can disrupt molecular pathways, synapses, neuronal and glial subpopulations, and local circuits in specific brain regions, as well as higher-order neural networks. Therefore, research must range from the study of large-scale brain network alterations to the microscopic and/or genetic abnormalities. Improving our knowledge of the pathophysiology of these conditions will enable not only to identify new potential therapeutic targets but also biomarkers, whose usefulness can range from detecting diseases in very early stages more likely to respond to disease-modifying treatments than advanced stages, to differentiate among similar conditions and to monitor response to treatments.

 

Research in this area focuses on defining the pathophysiological mechanisms involved in the loss of normal and neuronal plasticity related to these diseases using . A deeper understanding of neuronal connectivity and dynamics, signaling molecules, cell-cell interaction and epigenetic factors in the nervous system will enable us to devise new pharmacological targets for therapeutic strategies to prevent or delay nervous system diseases. 

 

Another therapeutic approach for nervous system disorders is neuroregenerative medicine. The institute is also interested in mimicking neural development on stem cells for replacing strategies as new therapies for diseases affecting the brain and spinal cord. 

 

Thus, the current structure and expertise of the Institute of Neurosciences constitute the best environment to conduct multidisciplinary and translational research to find therapeutic approaches for motor and cognitive dysfunctions.

Projects

 

  • Training for Advanced Stem Cell Technologies in Neurology (ASCTN-Training). Canals, Josep María. HORIZON 2020. (H2020-MSCA-ITN-2018) 813851
  • Misslocalization of astrocytic VCAM-1 in Megalencephalic leukoencepahlopathy.  Estevez, Raul. ELA2017-012F4 . ELA Research Foundation
  • A New family of sEH inhibitors for AD. CI17-00053 Pallas Lliberia, Merce Fundació Caixa de Pensions ‘La Caixa’
  • Ayudando al cerebro a reconstruirse: comprendiendo las propiedades físicas y metabólicas de los nichos neurogénicos en la búsqueda de terapias regenerativas para daño cerebral. BFU2017-83435-R Alcantara, Soledad. Ministerio de Economia y Competitividad.
  • Modulación de la vía del receptor de la insulina hipocampal como estrategia terapéutica para el tratamiento de la pérdida cognitiva. SAF2017-84283-R. Camins, Antonio. Ministerio de Economia y Competitividad
  • Iluminando los receptores de dopamina, adenosina y GPR37 en enfermedades neurológicas y neuropsiquiátricas. SAF2017-87349-R. Ciruela, Francisco. Ministerio de Economia y Competitividad
  • Nuevas aproximaciones frente al accidente cerebrovascular. De los mecanismos moleculares a los tratamientos farmacológicos. SAF2017-86622-C2-1-R. Soriano, Francesc Xavier. Ministerio de Economia y Competitividad
  • Estudio funcional del proteoma de los receptores AMPA. BFU2017-83317-P Soto Del Cerro, David Ministerio de Economia y Competitividad